NTRB Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: May 05, 2026
Report Source: 2026 Annual Report
Nutriband Inc. Stock Analysis NTRB
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Read More Nutriband Inc (NTRB) Chart
Key Statistics of Nutriband Inc (NTRB)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$3.51Volume
5414.00P/E Ratio (TTM)
-52 Week Range
Market Cap
49.60MAvg. Volume
9023.87Dividend Yield
-Financial Metrics & Statements of Nutriband Inc (NTRB)
FAQ's for Nutriband Inc (NTRB)
- According to Musaffa’s Shariah screening methodology, Nutriband Inc (NTRB) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.